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Abstract: Diabetic foot ulcers remain a major cause of morbidity. Signiﬁ  cant progress has been 
accomplished in ulcer healing by improved management of both ischemia and neuropathy in 
the diabetic foot. Nevertheless, there is a vital need for further improvement. Becaplermin gel 
represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate 
blood supply. Randomized controlled trials have shown that it is effective in increasing healing 
rates. However, this efﬁ  cacy has not translated to positive clinical experience, and the drug is not 
widely used. Moreover, becaplermin is an expensive medication. Even though it has repeatedly 
been estimated as cost-effective, its high cost may be prohibitive for some clinicians, especially 
in developing countries. Clearly, further work is needed to clarify whether use of becaplermin 
is justiﬁ  ed in everyday clinical practice. Future research also needs to assess the potential room 
for improvement with becaplermin, for instance by combination with other growth factors or 
by exploring alternative modes of drug delivery.
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Introduction
During the last 20 years, the world has witnessed an unparalleled increase in the 
incidence of diabetes mellitus, which has been identiﬁ  ed as a threatening epidemic 
(Wild et al 2004; Coliaguri et al 2005). Diabetic complications now account for the 
greater part of diabetes-related morbidity and healthcare costs (Boulton 2004; Bakker 
et al 2005; Boulton et al 2005). This holds especially true for the diabetic foot (Manes 
et al 2002; Boulton 2004; Boulton et al 2005). Indeed, diabetes is the major cause of 
nontraumatic lower-extremity amputations, reducing patient survival (Tentolouris et al 
2004) and inﬂ  icting an enormous ﬁ  nancial burden on society (Boulton et al 2005). It is 
not long ago that the International Working Group on the Diabetic Foot estimated the 
loss of a foot or leg attributable to diabetes every 30 seconds in the world (Bakker et al 
2005). Naturally, amputations are associated with substantial direct (ie, hospitalization 
and medication) as well as indirect (ie, loss of working days) costs (Boulton 2004; 
Boulton et al 2005).
It is now beyond dispute that the vast majority of amputations result from prior 
ulceration (Boulton 2004; Boulton et al 2005). Diabetic foot ulcers have a complex 
pathophysiology and are notoriously difﬁ  cult to heal (Boulton 2004; Bakker et al 
2005; Boulton et al 2005; Falanga 2005). The strategy to improve healing rates 
is based on the management of peripheral arterial disease, relief of high-pressure 
areas, aggressive debridement, and infection control (Watkins 2003; Boulton 2004; 
Edmonds 2004). At the same time, new treatments (growth factors, bioengineered 
skin substitutes, extracellular matrix proteins, and various other products) are con-
tinuously being explored (Jeffcoate et al 2004; Petrova and Edmonds 2006). This 
article reviews the use of becaplermin in the treatment of diabetic neuropathic foot Clinical Interventions in Aging 2008:3(2) 234
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ulcers. Becaplermin is recombinant platelet-derived growth 
factor commercially available as a gel form of 100 µg/g 
becaplermin. At the moment, it represents the only growth 
factor approved by American and European authorities for 
use in the treatment of foot ulceration.
Diabetic foot ulcers
Overall, one out of four diabetic patients runs the risk 
of developing foot ulceration in his lifetime (Reiber 
and Ledoux 2002). Foot ulcers result from the com-
posite interaction of three major entities: ischemia, 
neuropathy, and infection (Reiber et al 1999; Boulton 
2004; Edmonds 2004; Edmonds et al 2004a; Singh et al 
2005). Ischemia is ascribed to peripheral arterial disease, 
which is exceedingly frequent in diabetes, and leads to 
poor nutrient supply to peripheral tissue (Sumpio et al 
2003; Edmonds 2004). Neuropathy deprives patients of 
protective sensation, so that trauma (such as induced by 
stepping on a sharp object or, simply, due to ill-fitting 
shoes) may be unrecognized, leading to continuing tis-
sue destruction (Reiber et al 1999; Boulton et al 2004; 
Edmonds 2004; Singh et al 2005). Moreover, it leads 
to various foot deformities, resulting in abnormal focal 
pressure distribution on the plantar aspect of the foot 
(Reiber et al 1999; Boulton et al 2004; Edmonds 2004). 
Accordingly, some plantar sites have very high pressures 
and can easily develop ulcers (Reiber et al 1999; Boulton 
et al 2004; Edmonds 2004). Ultimately, more than half 
of chronic foot ulcers become infected (Pecoraro 1991). 
Infection is usually polymicrobial, with a combination 
of Gram-positive cocci, Gram-negative bacteria, and 
anaerobes, and may rapidly lead to necrosis (Edmonds 
2004; Edmonds et al 2004b).
A clinically useful classiﬁ  cation is into two categories: 
neuroischemic and neuropathic foot ulcers (Watkins 2003; 
Edmonds et al 2004a). In the former, neuropathy and isch-
emia coexist. The ulcer is usually located on the margins 
of the foot, has irregular shape and is typically painful, 
although peripheral neuropathy in some patients reduces or 
obviates pain. The foot is not warm, but may be cold and 
pulseless (Watkins 2003; Edmonds et al 2004a). The latter 
is most commonly found in high-pressure areas, notably 
prominent metatarsal heads and apices of toes (Watkins 
2003; Edmonds et al 2004a). It is usually painless, sur-
rounded by heavy callus formation and may be somewhat 
circular with a raised rim. The foot is warm, with intact 
pulses, while sensation is diminished (Watkins 2003; 
Boulton et al 2004; Edmonds et al 2004a). This distinction 
is of vital importance, because treatment differs according 
to etiology (Watkins 2003; Edmonds et al 2004a).
Overview of normal healing
Normal healing is a complex process requiring the collabo-
ration of numerous cells involved in the four overlapping 
phases of the healing cascade (Kirsner and Bogensberger 
2002; Jeffcoate et al 2004; Falanga 2005). These phases 
are, by tradition, classiﬁ  ed as hemostasis, inﬂ  ammation, 
migration/proliferation (otherwise known as maturation), 
and remodelling (Table 1) (Kirsner and Bogensberger 2002; 
Jeffcoate et al 2004; Falanga 2005) and will be very brieﬂ  y 
described below. Immediately after injury, vasoconstriction 
and platelet activation occur (hemostasis) (Jeffcoate et al 
2004; Falanga 2005). Platelets are the initiators of the clot-
ting cascade, but they also release growth factors (including 
platelet-derived growth factor, PDGF) and cytokines to 
attract other cells required for healing. In the next phase, 
inﬂ  ammatory cells (mainly neutrophils and macrophages, 
but also lymphocytes) enter the wound site by chemotaxis 
(Jeffcoate et al 2004; Falanga 2005). Neutrophils eliminate 
necrotic debris; macrophages remove bacteria and necrotic 
tissue, and they secrete growth factors to facilitate continu-
ation of healing; lymphocytes have a less clearly deﬁ  ned 
role. In the subsequent phase, migration/proliferation, wound 
contraction predominates (Jeffcoate et al 2004; Falanga 
2005). Tissue integrity is restored by ﬁ  broplasia, new vessel 
formation (neovascularization), and skin re-epithelialization 
(Jeffcoate et al 2004; Falanga 2005). Finally, remodeling is a 
slow dynamic process, in which cell density and vasculariza-
tion are diminished, while the total amount and the tensile 
strength of collagen increase (Jeffcoate et al 2004; Falanga 
Table 1 Overview of the phases of normal wound healing (Kirsner 
and Bogensberger 2002; Jeffcoate et al 2004; Falanga 2005)
Phase  Main cell types  Main activity
Coagulation Platelets  Vasoconstriction,  clot 
    formation, secretion of
    growth factors, and
   cytokines
Inﬂ  ammation  Leukocytes (neutrophils,  Chemotaxis of
 monocytes,  macrophages)  inﬂ  ammatory cells,
    eradication of bacteria,
    and necrotic debris
Migration/ Keratinocytes,  ﬁ  broblasts,  New vessel formation,
proliferation* endothelial  cells  ﬁ  broplasia
Remodeling Fibroblasts  Wound  contraction, 
    realignment of collagen
   ﬁ  bers to increase tensile
   strength,  scarring
Notes: *Otherwise known as maturation.Clinical Interventions in Aging 2008:3(2) 235
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2005). Moreover, collagen ﬁ  bers are progressively realigned 
and may lead to a variable amount of scarring (Kirsner and 
Bogensberger 2002; Jeffcoate et al 2004; Falanga 2005).
Impaired healing in diabetes
Healing of foot ulcers is characteristically impaired in dia-
betes (Edmonds 2004; Jeffcoate et al 2004; Falanga 2005). 
Therefore, patients often present with chronic, refractory, 
or recurrent foot ulcers (Edmonds 2004; Jeffcoate et al 
2004). The detrimental effect of diabetes on healing may 
be described as being exerted at two levels. The ﬁ  rst level 
comprises factors extrinsic to the wound itself, while the 
second level consists of intrinsic factors. Extrinsic factors 
can be summarized as the aforementioned triad of periph-
eral arterial occlusive disease, neuropathy, and infection 
(Edmonds 2004; Jeffcoate et al 2004). Naturally, peripheral 
arterial occlusive disease results in diminished oxygen supply 
to the components of the wound (Boulton 2004; Edmonds 
2004). If ischemia is severe, it may even prevent intrave-
nously administered antibiotics from achieving adequate 
concentration in the wound (Edmonds et al 2004b). Periph-
eral autonomic neuropathy may lead to disruption of the 
neurogenic control of small blood vessels, thereby resulting 
in diminished inﬂ  ammatory response and impaired wound 
healing (Parkhouse and Le Quesne 1988; Edmonds et al 
2004b). Infection complicates diabetic foot ulceration and 
aggravates cellular hypoxia by raising metabolic demands 
and by causing a neutrophilic vasculitis (Edmonds 2004; 
Jeffcoate et al 2004).
Intrinsic factors are now being increasingly investigated. 
It is thought that they affect local growth factors and miscel-
laneous wound healing constituents. Diabetic foot ulcers have 
been shown to exhibit abnormal or reduced expression of 
growth factors (Jeffcoate et al 2004; Falanga 2005). Dimin-
ished biologic action of growth factors due to nonenzymatic 
glycosylation is also a contributory factor (Jeffcoate et al 
2004). Some chronic diabetic foot ulcers also do not respond 
to local growth factors (Jude et al 2002; Black et al 2003). 
At a cellular level, reduced neutrophil chemotaxis, defec-
tive ﬁ  broblast action, and impaired capacity of other cell 
populations for migration and proliferation (Jude et al 2002; 
Jeffcoate et al 2004; Blakytny and Jude 2006) have been 
found. Finally, poor co-ordination of matrix metalloproteases 
with their tissue inhibitors exacerbates the impairment of 
healing (Jeffcoate et al 2004; Blakytny and Jude 2006).
Interestingly, hyperglycemia substantially affects both 
extrinsic and intrinsic factors. Not only has impaired meta-
bolic control been associated with increased prevalence of 
diabetic complications, notably neuropathy and vascular 
disease (Boulton 2004; Bakker et al 2005; Boulton et al 
2005), but it also impacts on the healing process itself 
(Papanas and Maltezos 2007). Indeed, the magnitude of 
hyperglycemia adds to the perturbation of the normal healing 
cascade. This negative effect is mediated via impaired func-
tion of intrinsic healing factors and via disordered participa-
tion of the cellular components of healing (Blakytny and 
Jude 2006). The recognition of this effect of hyperglycemia 
has obvious implications in clinical practice, which empha-
sizes the need for optimizing glycemic control.
Overview of the treatment
for diabetic foot ulcers
Treatment of diabetic foot ulcers needs to address the three 
major causal factors: ischemia, neuropathy, and infection 
(Watkins 2003; Boulton 2004; Edmonds 2004). In the 
neuroischemic foot, it is imperative to diagnose ischemia 
immediately and to restore normal blood ﬂ  ow to the limb. 
This can be achieved either surgically (bypass graft surgery) 
or intravascularly (percutaneous transluminal angioplasty) 
as required (Sumpio et al 2003; Edmonds 2004). In the 
neuropathic foot, the ulcerated area needs to be off-loaded 
with casts and cushioning insoles (Boulton 2004; Edmonds 
2004). Off-loading is combined with surgical debridement, 
which has been documented to promote granulation and 
wound closure (Edmonds 2004; Steed 2004). In both neu-
roischemic and neuropathic ulcers, a high index of suspicion 
for the diagnosis of infection is necessary to enable timely 
institution of antibiotics, choosing initially broad-spectrum 
agents and, subsequently, guided by appropriate cultures. 
These are usually swab cultures, although some authorities 
prefer deep tissue specimens (Edmonds 2004; Edmonds et al 
2004b). Advances in these treatment modalities have led to 
improvement in healing rates (Edmonds 2004). However, a 
signiﬁ  cant number of ulcers (as high as 49%) still may fail 
to heal (Margolis et al 2005a), indicating the need for further 
improvement.
Why use growth factors
to promote healing?
Growth factors have been shown to be omnipresent throughout 
the healing process (Köveker 2000; Cavanagh et al 2005). 
They act by binding to speciﬁ  c receptors in the plasma 
membranes of target cells, thereby activating signal trans-
duction mechanisms (Köveker 2000; Cavanagh et al 2005). 
At the cellular level, growth factors mediate macrophage 
migration, neovascularization, collagen synthesis, ﬁ  broblast Clinical Interventions in Aging 2008:3(2) 236
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proliferation, as well as ﬁ  nal re-epithelialization (Papanas 
and Maltezos 2007). Importantly, each growth factor acts 
on several cell lines, and this interaction enhances healing 
(Köveker 2000; Cavanagh et al 2005). The need to improve 
the aforementioned cellular functions has led to the ongo-
ing exploration of several growth factors (Köveker 2000; 
Cavanagh et al 2005). The rationale for this investigation is 
that while the restoration of a normal healing cascade may 
be elusive, any improvement in healing rates obtained with 
growth factors would be useful (Köveker 2000; Margolis 
et al 2005a).
The main growth factors involved in healing are: PDGF, 
ﬁ  broblast growth factor (FGF), vascular endothelial growth 
factor (VEGF), insulin-like growth factors (IGF1, IGF2), 
epidermal growth factor (EGF), and transforming growth 
factor β (TGF-β) (Köveker 2000; Jeffcoate 2004; Falanga 
2005). To date, only PDGF has been approved by the US 
Food and Drug Administration and European authori-
ties (Papanas and Maltezos 2007). Other growth factors 
include granulocyte-colony stimulating factor (GCSF) and 
nerve growth factor (NGF) (Papanas and Maltezos 2007). 
Initially, GCSF yielded very good results in infected dia-
betic foot ulcers without severe ischemia, but these were 
not replicated in the following studies, so that its clinical 
utility is rather questionable (Bennett et al 2003; Cruciani 
et al 2005; Papanas and Maltezos 2007). Experience with 
the other growth factors remains very limited (Papanas and 
Maltezos 2007).
PDGF: a protagonist in healing
Platelet-derived growth factor is mainly secreted by the plate-
lets’ α-granule, but it is also produced by other cells involved 
in early wound healing, ie, macrophages, endothelial cells, 
ﬁ  broblasts, and keratinocytes (Papanas and Maltezos 2007). 
PDGF is a powerful chemoattractant and mitogen, exerting 
its action on ﬁ  broblasts, smooth muscle cells, and endothelial 
cells (Papanas and Maltezos 2007). It also induces produc-
tion of ﬁ  bronectin and hyaluronic acid. There is a synergistic 
effect between PDGF and EGF, as well as TGF-β, and so 
PDGF has a pivotal role at all stages of wound healing (Nagai 
and Embil 2002; Papanas and Maltezos 2007).
PDGF is a dimer consisting of A and/or B chains, held 
together by a disulﬁ  de bond. Three isomers (AA, BB, and 
AB) have been isolated. The most common and potent iso-
mer is the BB isomer (Nagai and Embil 2002; Papanas and 
Maltezos 2007). Therefore, this isomer is the one used in the 
management of foot ulcers (Nagai and Embil 2002; Papanas 
and Maltezos 2007).
At present, recombinant PDGF is produced by DNA 
technology via incorporation of the gene for the β-chain of 
human PDGF into the yeast Saccharomyces cerevisiae. The 
resultant homodimeric protein, becaplermin, has a biologi-
cal activity similar to the endogenous PDGF-BB (Papanas 
and Maltezos 2007). A gel form of 100 µg/g becaplermin 
(Regranex® gel; Ortho-McNeil Pharmaceutical, Inc, Titus-
ville, NJ, USA) has been approved by the US Food and Drug 
Administration for the treatment of diabetic neuropathic 
ulcers with adequate peripheral circulation (Papanas and 
Maltezos 2007).
Efﬁ  cacy of becaplermin gel in 
neuropathic diabetic foot ulcers
The efficacy of becaplermin gel in the management of 
neuropathic ulcers has been documented by a number 
of randomized controlled trials, reviewed in more detail 
elsewhere (Papanas and Maltezos 2007). In these, 
922 patients were studied in total (Steed 1995; Smiell 
1998; Smiell et al 1999; Wieman et al 1998; Wieman 
1998; D’Hemercourt et al 1998; Embil et al 2000). Steed 
conducted the first randomized, double-blind placebo-
controlled trial (Steed 1995). He enrolled 118 patients, 
randomized to topical application of 30 µg/g becaplermin 
(N = 61) or placebo (N = 57). At the end of the study, 
48% (29/61) of ulcers healed in the becaplermin group 
vs. 25% (14/57) in the placebo group (p = 0.01) (Steed 
1995). There was also a non-significant trend (p = 0.09) 
for a greater median reduction in wound area in the 
becaplermin group (98.8%) as compared with the placebo 
group (82.1%).
Wieman and colleagues (1998) conducted a phase III ran-
domized double-blind placebo-controlled trial on the efﬁ  cacy 
and safety of becaplermin gel 30 µg/g (N = 132) vs. becapler-
min gel 100 µg/g (N = 123) vs. placebo (N = 127) (Wieman 
et al 1998). This work showed that becaplermin gel 100 µg/g 
added to standard wound care signiﬁ  cantly increased heal-
ing rates and decreased time to complete healing (Wieman 
et al 1998). Healing rates were 49.5% (61/123) in patients 
receiving becaplermin gel 100 µg/g, 36.3% (48/132) in those 
receiving becaplermin gel 30 µg/g, and 34.6% (44/127) in 
those receiving placebo. There was a signiﬁ  cant difference 
(p = 0.007) between high-dose becaplermin and placebo 
(Wieman et al 1998).
D’Hemercourt and colleagues (1998) compared 
three treatment regimens, ie, good wound care alone 
(N = 68), topical carboxymethylcellulose gel (N = 70), 
and becaplermin gel 100 µg/g added to standard wound Clinical Interventions in Aging 2008:3(2) 237
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care (N = 34). This study was statistically underpowered. 
However, becaplermin-treated patients did achieve a 
slightly higher healing rate (44.1%) in comparison with 
carboxymethylcellulose-treated patients (35.7%) and those 
receiving standard wound care alone (22%) (D’Hemercourt 
et al 1998).
A multi-center phase IIIB open-label study examined 
the efﬁ  cacy and safety of becaplermin gel 100 µg/g in 134 
patients (Embil et al 2000). It was shown that as high as 
57.5% of ulcers managed to heal with a mean time to wound 
closure of 63 days and a 21% six-month recurrence rate 
(Embil et al 2000).
Smiell and colleagues (1999) carried out a combined anal-
ysis based on all 922 patients recruited in the aforementioned 
studies (Steed 1995; Wieman et al 1998; D’Hemercourt et al 
1998; Embil et al 2000). This analysis provided evidence 
for a signiﬁ  cant beneﬁ  cial effect of becaplermin on healing. 
Indeed, becaplermin gel 100 µg/g signiﬁ  cantly (p = 0.0007) 
increased the likelihood of complete wound healing in com-
parison with placebo by 39% (50% vs. 36%, respectively). 
The drug also signiﬁ  cantly (p = 0.01) decreased the time to 
heal as compared with placebo by 30% (14.1 weeks vs. 20.1 
weeks, respectively) (Smiell et al 1999).
Table 2 summarizes the clinical trials on becapler-
min. In all studies, inclusion criteria were: a) chronic 
foot ulcer of duration 8 weeks); b) adequate arterial 
perfusion as documented by Ankle-Brachial Pressure 
Index 0.70 and/or transcutaneous partial pressure of 
oxygen 30 mmHg; c) absence of infection (Papanas 
and Maltezos 2007).
Safety of becaplermin gel in 
neuropathic diabetic foot ulcers
In all clinical trials, the safety proﬁ  le of becaplermin has 
consistently been found excellent, comparable with that of 
placebo (Papanas and Maltezos 2007). The clinical safety 
of the drug has also been speciﬁ  cally examined by Smiell 
(1998). It was demonstrated that rash occurred in 2% of 
becaplermin-treated patients and in 1% of those receiving 
placebo. Similarly, cardiovascular, respiratory, musculo-
skeletal and central or peripheral nervous system disorders 
did not differ between becaplermin- and placebo-treated 
subjects. Moreover, there were no neutralizing antibodies 
against becaplermin (Smiell 1998).
Cost-Effectiveness of becaplermin 
gel in neuropathic diabetic foot 
ulcers
Several authors have examined the cost-effectiveness of 
becaplermin (Persson et al 2000; Ghatnekar et al 2001; 
Kantor and Margolis 2001; Albert 2002; Sibbald et al 
2003). The drug has been shown to be cost-effective in 
Sweden (Persson et al 2000), in four European countries 
Table 2 Clinical trials of PDGF in diabetic foot ulcers. Copyright © 2007 SAGE Publications. Reproduced with permission from Papanas 
N, Maltezos E. 2007. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem Wounds, 
6:37–53
Platelet-derived growth factor
Author Year Study  design Comparison Main  ﬁ  ndings
Steed 1995 Double blind placebo 
controlled
Topical PDGF gel 30 µg/g vs. 
placebo
Complete ulcer closure at 20 
weeks: 48% vs. 25%, p = 0.01
Wieman 1998 Double blind placebo 
controlled
Topical PDGF gel 100 µg/g 
vs. 30 vs. µg/g vs. placebo
Complete ulcer closure: 49.5% 
vs. 36% vs. 35%, p = 0.007
Mean time to heal: 86 days (100 
µg/g) vs. 127 days (placebo)
D’Hemercourt 1998 Randomized double-blind 
placebo-controlled
Topical PDGF gel 100 µg/g 
vs. carboxymethylcellulose 
gel vs. good ulcer care
Complete ulcer closure: 44.1% 
vs. 35.7% vs. 22%
Embil 2000 Phase IIIB open-label Safety of topical PDGF gel 
100 µg/g
Complete ulcer closure: 57.5%
Mean time to heal: 63 days
Smiell 1999 Meta-analysis* Topical PDGF gel 100 µg/g 
vs. placebo
Complete ulcer closure: 50% vs. 
36%, p = 0.0007
Mean time to heal: 14.1 weeks 
vs. 20.1 weeks, p = 0.01
Notes: *Meta-analysis of the studies by Steed (1995), Wieman (1998), D’Hemercourt (1998), and Embil (2000).Clinical Interventions in Aging 2008:3(2) 238
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(Sweden, Switzerland, UK, and France) (Ghatnekar et al 
2001) and in the USA (Kantor and Margolis 2001). In the 
USA, the addition of becaplermin is associated with an 
initial higher cost, but this effectively reduces expenses 
resulting from more prolonged treatment, namely ofﬁ  ce 
visits and dressings, as well as complication rates (Albert 
2002). Indeed, adding up to 20 weeks of becaplermin to 
best medical care over 12 months resulted in 26 fewer 
ulcer-days per patient, equating to an avoided cost-
effectiveness ratio of US$6 per ulcer-day (Sibbald et al 
2003). A cost-effectiveness study of becaplermin in other 
parts of the world, including developing countries, is 
missing (Papanas and Maltezos 2007).
Becaplermin gel in actual clinical 
practice: expectations still not met
Although becaplermin has been shown to significantly 
improve healing rates in small randomized controlled trials, 
this efﬁ  cacy has not yet translated to positive clinical experi-
ence (Papanas and Maltezos 2007). This discrepancy may be 
ascribed to the fact that randomized trials are conducted under 
tightly controlled conditions, whereas clinicians encounter 
patients in actual practice, rather than in the ideal world 
(Papanas and Maltezos 2007). Consequently, efﬁ  cacy of 
the drug under study in the setting of a controlled trial does 
not necessarily translate into effectiveness of the same drug 
in everyday clinical situation. This prompted Margolis and 
colleagues (2005b) to examine the effectiveness of becapl-
ermin in actual clinical practice. Their study included 24,898 
subjects with neuropathic foot ulceration between 1998 and 
2004, of whom 2394 (9.6%) received becaplermin (Margolis 
et al 2005b). Healing rates were 33.5% and 25.8% in the 
becaplermin and control group respectively (p  0.0001) 
(Margolis et al 2005b). Accordingly, becaplermin increased 
the likelihood of healing by 32% (RR = 1.32). Moreover, 
amputation rates were signiﬁ  cantly (p  0.0001) lower in the 
becaplermin (4.9%) than in the control group (6.4%), despite 
the fact that patients receiving becaplermin had considerable 
adverse risk factors for healing (increased wound duration 
and size, increased wound grade at initial visit) (Margolis 
et al 2005b).
The study by Margolis and colleagues (2005b) again 
suggested that becaplermin should be expected to improve 
healing rates in practice. However, this expectation has not 
been met, so that the drug is still not widely used. In line 
with this clinical wisdom, the International Working Group 
on the Diabetic Foot has in a very recent international 
consensus statement suggested that evidence justifying the 
use of becaplermin remains to be conﬁ  rmed (International 
Working Group on the Diabetic Foot 2007). Obviously, fur-
ther improvement is required to utilize the beneﬁ  cial potential 
of becaplermin in everyday clinical situations.
Implications for further 
improvement with becaplermin
The recognition that routine clinical experience with beca-
plermin in the management of diabetic foot ulcers has been 
less successful than hoped for (International Working Group 
on the Diabetic Foot 2007; Papanas and Maltezos 2007) has 
led to the exploration of potential areas of improvement 
with the use of this agent. It has been hypothesized that 
application of a growth factor in a liquid or gel form might 
not ensure availability to the healing cells in the wound 
site (Margolis et al 2000a). Hence, alternative modes of 
growth factor delivery have been explored (Eming et al 
1999; Liechty et al 1999; Breitbart et al 2003; Man et al 
2005). Encapsulation of growth factors into red blood 
cells or microspheres, application of skin substitutes over-
expressing growth factors, genetic manipulation, and intra-
arterial growth factor infusion represent the most important 
alternatives (Eming et al 1999; Liechty et al 1999; Breitbart 
et al 2003; Man et al 2005). Most of the work with alterna-
tive modes of growth factor delivery is still experimental, 
and clinical experience is eagerly awaited (Papanas and 
Maltezos 2007).
Combination of becaplermin with other growth factors 
to enhance healing is a further attractive notion (Papanas 
and Maltezos 2007). This combination is justiﬁ  ed on the 
basis of the naturally occurring interaction between growth 
factors during normal healing (Papanas and Maltezos 2007). 
A study of the effect of growth factors on healing in full-
thickness skin wounds created on the backs of diabetic mice 
has, indeed, provided evidence for a synergistic action of the 
PDGF and TGF-α combination (Brown et al 1994).
Additionally, the option of longer exposure time of the 
wound to becaplermin to optimize the frequency of drug 
application and dressing changes is also highly interesting 
(Castronuovo et al 1998). However, this possibility remains 
hitherto unexplored (Papanas and Maltezos 2007).
Finally, it should not escape our notice that becaplermin 
has been mostly studied in patients with type 2 diabetes. This 
type of diabetes is now showing an unprecedented epidemic 
across the world (Wild et al 2004; Coliaguri et al 2005). Thus, 
the greater proportion of foot ulcers is encountered in patients 
with type 2 diabetes (Boulton 2004; Bakker et al 2005; 
Boulton et al 2005). However, it might be useful to examine if Clinical Interventions in Aging 2008:3(2) 239
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there is any difference in the efﬁ  cacy of becaplermin between 
patients with type 1 and those with type 2 diabetes.
Conclusions
The diabetic foot continues to be a major cause of morbidity 
across the world, and there is a fundamental need to improve 
the outcomes (Bakker et al 2005; Papanas et al 2006a). The 
development of growth factors to promote wound healing 
represents an important step forward, but there is still a 
long way to go. Becaplermin is the only growth factor cur-
rently approved for use in diabetic foot ulcers (Papanas and 
Maltezos 2007). Nonetheless, it may only be used in neuro-
pathic ulcers with adequate peripheral circulation (Papanas 
and Maltezos 2007). More importantly, it is a widespread 
clinical impression that its success in everyday practice has 
been less triumphant than might have been anticipated on the 
grounds of randomized controlled trials (International Work-
ing Group on the Diabetic Foot 2007; Papanas and Maltezos 
2007). Last but not least, becaplermin is an expensive 
medication. Even though it has repeatedly been estimated 
as cost-effective in the Western world, its high cost may be 
prohibitive in developing countries, which are responsible for 
a great part of the global burden of the diabetic foot (Bakker 
et al 2005; Boulton et al 2005).
Clearly, further work is needed to render becaplermin a 
more effective tool. Some of the potential areas of improve-
ment have already been identiﬁ  ed as improved drug delivery 
to the ulcer and combination therapy with other growth 
factors to achieve a synergistic effect (Brown et al 1994; 
Castronuovo et al 1998; Man et al 2005). Of equal impor-
tance is the necessity for a more precise deﬁ  nition of the 
role of becaplermin in the overall treatment strategy for the 
diabetic foot (Papanas and Maltezos 2007). Clinicians need 
evidence-based guidelines specifying when to use standard 
care and when to consider the use of this agent. Should they, 
for instance, only use becaplermin in ulcers that have already 
proved refractory to established treatment or should they try 
to predict which ulcers are more difﬁ  cult to heal (Margolis 
et al 2000b) and might beneﬁ  t from earlier initiation of 
growth factor treatment?
Finally, it should not be underestimated that the use of 
becaplermin, as indeed of every new therapeutic modality, 
should not be practiced alone, but be incorporated in a holistic 
strategic approach. Essentially, only multidisciplinary foot 
clinics have demonstrated that the reduction of lower-limb 
amputations is possible (Edmonds et al 1986; Holstein and 
Sorensen 1999; Holstein et al 2000, 2001; van Houtum et al 
2004). Knowledge needs to be implemented more vigorously, 
coupled with constant education of patients and physicians 
alike, emphasizing on primary and secondary prevention 
(Papanas et al 2005, 2006b). Numerous obstacles to effec-
tive foot care still prevail and need to be abolished to reduce 
amputations (van Houtum 2005; Papanas et al 2006b).
Disclosure
The authors have no conﬂ  ict of interest in relation to the 
products discussed.
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